How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

254 results for

Alpha-Hydroxy acid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Toxicity, Alcohols (Overview)

to glycolic acid is somewhat rapid. In contrast, the conversion of glycolic acid to glyoxylic acid is slower and is the rate-limiting step in the metabolism of ethylene glycol. Glyoxylic acid is subsequently metabolized into several different products, including oxalic acid (oxalate), glycine, and alpha-hydroxy-beta-ketoadipate. The conversion to glycine requires pyridoxine as a cofactor, while the conversion to alpha-hydroxy-beta-ketoadipate requires thiamine as a cofactor. The oxalic acid combines (...) prolonged inhalation or skin absorption. [ , , , ] Methanol is rapidly absorbed from the gastric mucosa, and achieves a maximal concentration 30-90 minutes after ingestion. [ ] Methanol is primarily metabolized in the liver via alcohol dehydrogenase into formaldehyde. Formaldehyde is subsequently metabolized via aldehyde dehydrogenase into formic acid, which ultimately is metabolized to folic acid, folinic acid, carbon dioxide, and water. A small portion is excreted unchanged by the lungs. Formic acid

2014 eMedicine Emergency Medicine

122. Efficacy and Safety Study of Kinerase® for Treatment of Cutaneous Facial Photodamage

who have used topical alpha-hydroxy acid skin care products in the month preceding the screening visit. Subjects currently on any anti-aging products and who wish to continue use of their products. Subjects requiring concurrent treatment that would interfere with the study assessments. Pregnant or lactating female subjects. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using

2013 Clinical Trials

123. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus

-bile acid) at Day 14, Day 28, and Day 42 [ Time Frame: Pre-dose, and at 2 and 5 hour (h) post-dose on Days 14, 28 and 42 ] Serum samples were collected on Days 14, 28 and 42 for T bile acid. Area under the curve (AUC) over the given time interval was obtained using the repeated measures Analysis of covariance (ANCOVA) analysis. AUC of serum profiles of 7-alpha hydroxy 4-cholesten-3-one (C4) at Day 14, Day 28, and Day 42 [ Time Frame: Pre-dose, and at 2 and 5 hr post-dose on Days 14, 28 and 42 (...) -blind, placebo-controlled study to assess safety and tolerability of GSK2330672 administration in subjects with primary biliary cirrhosis (PBC) and symptoms of pruritus. It is a double-blind, crossover study with subjects receiving placebo or GSK23306772 in random order during two 14-day treatment periods. Additionally, the study will determine GSK2330672 exposure and interactions with ursodeoxycholic acid (UDCA). The total duration of subject participation will be 14 weeks for screening (45 days

2013 Clinical Trials

124. Efficacy and Safety of Kinetin 0.1% for Treatment of Skin Photoaging

or adapalene in the 2 months prior to the screening visit Used topical alpha-hydroxy acid skincare products in the month preceding the screening visit On any anti-aging products and who wish to continue use of their products Requiring concurrent treatment that would interfere with the study assessments Pregnant or lactating females Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using (...) other commonly used anti-aging products. The Kinerase cream contains: Water, glyceryl stearate, propylene glycol, butylenes glycol, glycerin, cetyl alcohol, stearic acid, isopropyl palmitate, squalene, stearyl alcohol, glycene soja sterols, dimethicone, laureth-23, aloe barbadensis leaf juice, phenoxyethanol, carbomer, ethylhexyglycerin, sodium hydroxide, soluble collagen, kinetin, panthenol, tocopherol, citric acid, sodium citrate, hydrolysed elastin. Other: Kinetin, N6-furfuryladenine, 0.1% Other

2013 Clinical Trials

125. An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine

formation or hypertrophic scars. Use of isotretinoin within 12 months of the baseline visit. Use of per oral or topical (facial) substances containing retinoids, bensoyl peroxide, alpha-hydroxy acid at a concentration above 10% or beta-hydroxy acid at a concentration above 2% or antibiotics within four months of the baseline visit. Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation (e.g. aspirin or other nonsteroidal anti-inflammatory drugs [NSAIDs]), Omega-3 (...) Posted: January 25, 2016 Last Verified: December 2015 Additional relevant MeSH terms: Layout table for MeSH terms Lidocaine Hyaluronic Acid Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Anti-Arrhythmia Agents Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Adjuvants, Immunologic Immunologic Factors

2013 Clinical Trials

126. Treatment of Periorbital and Perioral Wrinkles With the Applications of the Iluminage Diode Laser

or his designees Exclusion Criteria: Subjects who currently use or have used in the prior 30 days any skin products that contain alpha hydroxy acids (AHA) e.g. glycolic, lactic, citric, or mendelic acid containing products or retinol/tretinoin containing products or exfoliating washes, masks or scrubs or other micro-dermabrasion skin care products. on the laser application areas Subjects who are unwilling to maintain their daily skin care regimen for the duration of the study, Subjects who have any

2013 Clinical Trials

127. Dehydrated Human Amnion/Chorion Membrane (dHACM) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face

anesthetics of the amide or ester family Known allergies to gentamicin and/or streptomycin Receiving any topical products containing alpha-hydroxy acids, salicylic acid, and Vitamins C or E (including derivatives of Vitamins C or E) on the face within 14 days prior to or during the study period, other than the ingredients of the study products Receiving and/or has had a microdermabrasion (light or medium skin peel) treatment on their face within 30 days prior to or during the study period Using any (...) the time of the study or has used self-tanner within 7 days of study entry History of or the presence of any skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis) Active bacterial, fungal, or viral infection History of Herpes Simplex Virus to the facial and/or perioral areas Known allergies or sensitivities to benzocaine, lidocaine, tetracaine, PABA (para-aminobenzoic acid), or other local

2013 Clinical Trials

128. Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands

that is either a)the experimental treatment or b) the placebo control. Drug: DerMend Moisturizing Bruise Formula DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients. Other Name: DerMend Placebo Comparator: Non-active placebo control Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which (...) or cooperate with the Investigator due to language problems, poor mental development, or impaired cerebral function; History of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure, including known sensitivities to any ingredient; Concomitant use of potentially irritating over-the-counter products that contain ingredients such as arnica, alpha-hydroxy acid, salicylic acid, retinol or glycolic acid; Subjects who present with one or more

2013 Clinical Trials

129. Bladder Antispasmodic

to reduce bladder contractions by relaxing bladder smooth muscle. Concepts Pharmacologic Substance ( T121 ) , Organic Chemical ( T109 ) MSH SnomedCT 35768004 , 372717000 LNC LP18095-7, MTHU003379 English 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate , 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate , oxybutynin , OXYBUTYNIN @ @ UNIDENTIFIED , OXYBUTYNIN UNIDENTIFIED , Benzeneacetic Acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl Ester , 4 (...) therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. Concepts Pharmacologic Substance ( T121 ) , Organic Chemical ( T109 ) MSH SnomedCT 372768002 , 53641000 English Flavoxate , 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester , Flavoxate [Chemical/Ingredient] , flavoxATE , flavoxate , FLAVOXATE , Flavoxate (product

2015 FP Notebook

130. Chemical Peel

, Chemexfoliation II. Mechanism Chemical exfoliation of superficial skin layers using acids or enzymes (e.g. hydroxy acids) III. Indications (same indications as for Microdermabrasion) Benign epidermal pigmentation Rough skin Superficial acne scars IV. Dosing Course of 6 treatments every 4 weeks with maintenance treatments every 1-3 months V. Preparations Alpha hydroxy acids Lactid acid Beta hydroxy acids Salicylic acid VI. Efficacy Results are temporary VII. Advantages Inexpensive VIII. Disadvantages Difficult

2015 FP Notebook

131. Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris

ingredients such as benzoyl peroxide,salicylic acid,alpha-hydroxy acid,retinol or glycolic acids Have not undergone the specified washouts for topical preparations,systemic medications and procedures noted in the protocol Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier

2012 Clinical Trials

132. Trial Comparing the Effects of Intermittent Vismodegib Versus Photodynamic Therapy in Patients With Multiple Basal Cell Carcinomas

than 5% of the skin (ii) retinoids systemically or topically to more than 5% of the skin during the six months prior to study entry; (iii) alpha-hydroxy acids to more than 5% of the skin during the six months prior to study entry (iv) 5-fluorouracil or imiquimod systemically or topically to the skin above the knees during the six months prior to study entry. (v) treatment with systemic chemotherapy within one year prior to starting study medication. has a history of hypersensitivity to any (...) Gorlin's Syndrome Drug: Vismodegib Drug: Aminolevulinic acid %20 topical solution Phase 2 Detailed Description: This is a Phase II, 28 month, randomized, two arm multicenter clinical study design. During the initial 7 months of the study, all 24 subjects will receive vismodegib, 150mg/day. They then will be randomized in a 1:1 ratio to receive intermittent vismodegib, 150 mg/day, during months 10-13, 16-19, and 22-25 or to receive treatment with PDT at month 10 and at three month intervals thereafter

2012 Clinical Trials

133. Clinical and Usability Study to Determine Safety and Efficacy of the Clear Device for Acne Treatment

chemical peeling within the last 3 months. Received treatment with light, laser, radiofrequency (RF), or other devices in the treated area within 6 months. Used isotretinoin (Accutane®) within 6 months prior to treatment. Using of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) 1 week before and after each treatment session. Subjects that are currently or have recently been treated with Alpha-Hydroxi Acids (AHAs), Beta-Hydroxi Acids (BHAs), Retin-A®, topical retinoids (...) Inclusion Criteria: Presence of mild to moderate acne. Skin Type I to VI (Fitzpatrick). Males or females who are 21-65 years old. Willingness to follow the treatment schedule, post-treatment care and have photographs taken. Exclusion Criteria: Pacemaker or internal defibrillator. Permanent implant in the treated area, such as metal plates and screws or silicon, unless deep enough in the bone. Skin areas that have been injected with Botox/ Hyaluronic acid /collagen/fat injections or other augmentation

2012 Clinical Trials

134. An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

to use: Shampoos that contain no corticosteroid; Bland (without beta or alpha hydroxy acids or containing no psoriasis treatment) emollients; Low potency topical corticosteroids on the palms, soles, face, inframammary area, and groin only. Patient who cannot avoid UVB (Ultraviolet-B) phototherapy for at least 14 days prior to the Baseline (Week 0) visit and during the study. Patient who cannot avoid PUVA (psoralen + ultraviolet A) phototherapy for at least 28 days prior to the Baseline (Week 0) visit (...) included laboratory data, vital signs and adverse events. Change From Baseline in Uric Acid [ Time Frame: Baseline and Week 24 (or Early Termination Visit) ] Safety variables included laboratory data, vital signs and adverse events. Change From Baseline in Inorganic Phosphate [ Time Frame: Baseline and Week 24 (or Early Termination Visit) ] Safety variables included laboratory data, vital signs and adverse events. Change From Baseline in Calcium, Sodium and Potassium [ Time Frame: Baseline and Week 24

2012 Clinical Trials

135. A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea

hormonal contraceptives). Use of high strength (20% or above) alpha-hydroxy acid for facial peel or any type of chemical facial skin peel or other significant cosmetic procedures within 2 months of the study start. Receipt of any drug as part of a research study within 30 days prior to dosing. Employees of the research center or Investigator. Previous participation in this study. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your

2012 Clinical Trials

136. Structure, composition, physical properties, and turnover of proliferated peroxisomes. A study of the trophic effects of Su-13437 on rat liver Full Text available with Trip Pro

, urate oxidase, L-alpha-hydroxy acid oxidase, and D-amino acid oxidase, respectively. For catalase the change results from a decrease in particle-bound activity and a fivefold increase in soluble activity. The average diameter of peroxisome sections is 0.58 +/- 0.15 mum in controls and 0.73 +/- 0.25 mum after treatment. Therefore, the measured peroxisomal enzymes are highly diluted in proliferated particles. After tissue fractionation, approximately one-half of the normal peroxisomes and all (...) Structure, composition, physical properties, and turnover of proliferated peroxisomes. A study of the trophic effects of Su-13437 on rat liver Peroxisome proliferation has been induced with 2-methyl-2-(p-[1,2,3,4-tetrahydro-1-naphthyl]-phenoxy)-propionic acid (Su-13437). DNA, protein, cytochrome oxidase, glucose-6-phosphatase, and acid phosphatase concentrations remain almost constant. Peroxisomal enzyme activities change to approximately 165%, 50%, 30%, and 0% of the controls for catalase

1975 The Journal of cell biology

137. Biphasic Inhibition of Photosynthesis in Powdery Mildewed Barley Full Text available with Trip Pro

physiological concentrations of CO(2). Under high CO(2) (1.0%) a stimulation was observed during early stages of infection. The inhibition in low CO(2) and stimulation in high CO(2) of infected host photosynthesis was shown to occur in healthy host tissue when in the presence of 10(-2)m alpha-hydroxy-2-pyridinemethanesulfonic acid. The possible significance of these similar results is discussed.

1970 Plant physiology

138. DISTRIBUTION OF PEROXISOMES (MICROBODIES) IN THE NEPHRON OF THE RAT : A Cytochemical Study Full Text available with Trip Pro

DISTRIBUTION OF PEROXISOMES (MICROBODIES) IN THE NEPHRON OF THE RAT : A Cytochemical Study The distribution of peroxisomes (microbodies) in the rat nephron was studied cytochemically, using glutaraldehyde- or formaldehyde-fixed tissue, by means of alpha-hydroxy acid oxidase activity in light microscopy or oxidation of 3,3'-diaminobenzidine (DAB) at pH 9 in both light and electron microscopy.The two cytochemical methods show peroxisomes to be nearly sperical particles found only in cells (...) of the proximal convoluted tubule. Lysosomes were identified in the same or parallel sections, with beta-glycerophosphate or 5'-cytidylic acid as substrate. They are found in all cells of the nephron. These cytochemical methods visualize the two organelles for light microscopy; they also permit unequivocal differentiation of all kidney peroxisomes from lysosomes in electron micrographs. Peroxisomes are larger and more reactive in the cells of the pars descendens (P(3) segment) of the proximal convolution

1969 The Journal of cell biology

139. Anaerobic Degradation of the Benzene Nucleus by a Facultatively Anaerobic Microorganism Full Text available with Trip Pro

cleavage catalyzed by protocatechuic acid-4,5-oxygenase, to yield alpha-hydroxy-gamma-carboxymuconic semialdehyde. Pseudomonas PN-1 grew rapidly on p-hydroxybenzoate under strictly anaerobic conditions, provided nitrate was present, even though protocatechuic acid-4,5-oxygenase was repressed. Suspensions of cells grown anaerobically on p-hydroxybenzoate oxidized benzoate with nitrate and produced 4 to 5 mumoles of CO(2) per mumole of benzoate added; these cells did not oxidize benzoate aerobically

1970 Journal of bacteriology

140. THE SYNTHESIS AND TURNOVER OF RAT LIVER PEROXISOMES : I. Fractionation of Peroxisome Proteins Full Text available with Trip Pro

THE SYNTHESIS AND TURNOVER OF RAT LIVER PEROXISOMES : I. Fractionation of Peroxisome Proteins Rat liver peroxisomes isolated by density gradient centrifugation were disrupted at pH 9, and subdivided into a soluble fraction containing 90% of their total proteins and virtually all of their catalase, D-amino acid oxidase, L-alpha-hydroxy acid oxidase and isocitrate dehydrogenase activities, and a core fraction containing urate oxidase and 10% of the total proteins. The soluble proteins were (...) chromatographed on Sephadex G-200, diethylaminoethyl (DEAE)-cellulose, hydroxylapatite, and sulfoethyl (SE)-Sephadex. None of these methods provided complete separation of the protein components, but these could be distributed into peaks in which the specific activities of different enzymes were substantially increased. Catalase, D-amino acid oxidase, and L-alpha-hydroxy acid oxidase contribute a maximum of 16, 2, and 4%, respectively, of the protein of the peroxisome. The contribution of isocitrate

1969 The Journal of cell biology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>